Pharma BD Deal Intelligence
BMS / Amylin Pharmaceuticals: Partially Achieved (Score: 46/100)
Full analysis, sources & comparables →BMS acquired Amylin Pharmaceuticals for $5.3B for diabetes treatment portfolio.
AstraZeneca made a $3.4 billion cash payment as part of Bristol-Myers Squibb's acquisition of Amylin Pharmaceuticals, making Amylin a wholly owned subsidiary…
Bristol-Myers Squibb agreed to acquire Amylin Pharmaceuticals for $31 per share or approximately $5.3 billion, with total transaction value of about $7 billion…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
BMS acquired Amylin Pharmaceuticals for $5.3B for diabetes treatment portfolio.
BMS / Amylin Pharmaceuticals: Partially Achieved (Score: 46/100)
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Amylin Pharmaceuticals (this deal) | 2012 | $5.3B | 39 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2012 deals · Bristol-Myers Squibb Company deals · Metabolic deals